{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:39:51Z","timestamp":1791193191774,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1002\/jps.21387","type":"journal-article","created":{"date-parts":[[2008,4,8]],"date-time":"2008-04-08T15:46:21Z","timestamp":1207669581000},"page":"5229-5239","source":"Crossref","is-referenced-by-count":12,"title":["Crystal chemistry of sibutramine: Thermal, diffractometric and spectroscopic characterization"],"prefix":"10.1016","volume":"97","author":[{"given":"Elisabetta","family":"Maccaroni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Alberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Malpezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norberto","family":"Masciocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Pellegatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1002\/jps.21387_bb0010","unstructured":"Kiyoharu Ukai S,Chiharu Masuda M,Satoko Kubo O,Teruo Mukai J,Terutake Nakagawa O.1990. Use of N,N-dimethyl-1-[1-(4-chlorophenyl)-cyclobutyl]-3-methylbutylamine. US patent No4,939,175."},{"key":"10.1002\/jps.21387_bb0015","unstructured":"Kozlik A,Wilmshurst EC,Jefferey JE.1982. Therapeutic agents. GB patent No2,098,602."},{"key":"10.1002\/jps.21387_bb0020","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2165\/00003495-199856060-00019","article-title":"Sibutramine: A review of its contribution to the management of obesity","volume":"56","author":"McNeely","year":"1998","journal-title":"Drugs"},{"key":"10.1002\/jps.21387_bb0025","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ddr.20013","article-title":"Monoamine reuptake inhibitors: Highlights of recent research development","volume":"65","author":"Walter","year":"2005","journal-title":"Drug Dev Res"},{"key":"10.1002\/jps.21387_bb0030","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2165\/00003495-200565100-00006","article-title":"Pharmacotherapy for obesity","volume":"65","author":"Ioannides-Demos","year":"2005","journal-title":"Drugs"},{"key":"10.1002\/jps.21387_bb0035","unstructured":"Rao DR,Kankan RN.2004.Sibutramine free base in crystalline form and its pharmaceutical use. WO2004\/099119."},{"key":"10.1002\/jps.21387_bb0040","unstructured":"Edward JJ,Derek WN.1987. N-dimethyl-1-1-(4-chlorophenyl)cyclobutyl-3-methylbutylamine salt. GB patent No2,184,122."},{"key":"10.1002\/jps.21387_bb0045","unstructured":"Kang T-W,Jeon K-F,Shon H-J,Choi W-K,Chang K-Y,Jin K-Y,Lee K-S.2006.Anhydrous sibutramine malates and preparation method thereof. WO2006090999."},{"key":"10.1002\/jps.21387_bb0050","unstructured":"Lee J-H,Park G-S,Lee J-C,Kim H-K,Chang Y-K,Lee G-S.2004.Pharmaceutical composition comprosing crystalline sibutramine methanesulfonate hemihydrate. WO2004\/030663."},{"key":"10.1002\/jps.21387_bb0055","first-page":"513","article-title":"Crystal structure of N-(1-(1-(p-chlorophenyl)cyclobutyl)-3-methylbutyl)-N,N-dimethylamine hydrochloride monohydrate (C17H27NCl)Cl\u00b7H2O","volume":"220","author":"Chen","year":"2005","journal-title":"Z. Kristallogr"},{"key":"10.1002\/jps.21387_bb0060","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1016\/S0957-4166(99)00511-X","article-title":"First preparation of enantiomerically pure sibutramine and its major metabolite, and determination of their absolute configuration by single crystal X-ray analysis","volume":"10","author":"Fang","year":"1999","journal-title":"Tetrahedron Asymmetry"},{"key":"10.1002\/jps.21387_bb0065","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0957-4166(02)00086-1","article-title":"First practical synthesis of enantiomerically pure (R)- and (S)-desmethylsibutramine (DMS) and unambiguous determination of their absolute configuration by single crystal X-ray analysis","volume":"13","author":"Han","year":"2002","journal-title":"Tetrahedron Asymmetry"},{"key":"10.1002\/jps.21387_bb0070","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1021\/ol0507017","article-title":"Control of Diastereoselectivity by solvent effects in the addition of Grignard reagents to enantiopure t-butylsulfinimide: Syntheses of the stereoisomers of the hydroxyl derivatives of sibutramine","volume":"7","author":"Lu","year":"2005","journal-title":"Org Lett"},{"key":"10.1002\/jps.21387_bb0075","series-title":"SHELXL-97 Program for Crystal Structure Refinement","author":"Sheldrick","year":"1997"},{"key":"10.1002\/jps.21387_bb0080","series-title":"TOPAS Version 3.1. Bruker AXS GmbH","author":"Coelho","year":"2003"},{"key":"10.1002\/jps.21387_bb0085","unstructured":"Given that the supplied material is racemic, the most obvious space group assignment was P-1. Actually, powders of S could as well be a conglomerate of P1 enantiomorphic forms, each one containing two homochiral crystallographically independent molecules, Z\u2032 = 2, but this was excluded by successful structure solution in P-1."},{"key":"10.1002\/jps.21387_bb0090","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0022-4596(92)90081-6","article-title":"Crystal structure and thermolysis of K2(H5O2)Al2Fg","volume":"98","author":"Le Bail","year":"1992","journal-title":"J Solid State Chem"},{"key":"10.1002\/jps.21387_bb0095","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1107\/S0021889869006558","article-title":"A profile refinement method for nuclear and magnetic structures","volume":"2","author":"Rietveld","year":"1969","journal-title":"J Appl Cryst"},{"key":"10.1002\/jps.21387_bb0100","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1039\/p19960002583","article-title":"Synthesis of sibutramine, a novel cyclobutylalkylamine useful in the treatment of obesity, and its major human metabolites","volume":"1","author":"Jeffery","year":"1996","journal-title":"J Chem Soc Perkin Trans"},{"key":"10.1002\/jps.21387_bb0105","first-page":"20","article-title":"Isolation and identification of a sibutramine analogue in a healthy food for weight loss","volume":"15","author":"Lai","year":"2007","journal-title":"J Food Drug Anal"},{"key":"10.1002\/jps.21387_bb0110","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0263-7855(89)80021-9","article-title":"SMILE\u2013Shaded molecular imaging on low-cost Equipment","volume":"7","author":"Eufri","year":"1989","journal-title":"J Mol Graph"},{"key":"10.1002\/jps.21387_bb0115","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1351\/pac197645010011","article-title":"Commission on Nomenclature of Organic Chemistry, Section E: Stereochemistry (Recommendations 1974)","volume":"45","year":"1976","journal-title":"Pure Appl Chem"},{"key":"10.1002\/jps.21387_bb0120","unstructured":"Published cell parameters: a = 13.442(3) \u00c5, b = 9.374(2) \u00c5, c = 30.110(7) \u00c5, V = 3794 \u00c53, Z = 8."},{"key":"10.1002\/jps.21387_bb0125","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1039\/B307145F","article-title":"Polymorphism of dehydrocholic acid: Crystal structure of the \u03b2-phase and guest-mediated solid phase conversion","volume":"27","author":"Fantin","year":"2003","journal-title":"New J Chem"},{"key":"10.1002\/jps.21387_bb0130","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/jps.20330","article-title":"Single crystal and powder diffraction characterization of three polymorphic forms of Acitretin","volume":"94","author":"Malpezzi","year":"2005","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21387_bb0135","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ijpharm.2007.09.028","article-title":"Polymorphism of linezolid: A combined single-crystal, powder diffraction and NMR study","volume":"351","author":"Maccaroni","year":"2008","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.21387_bb0140","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.crci.2005.01.015","article-title":"Structural powder diffraction characterization of organometallic species: The role of complementary information","volume":"8","author":"Masciocchi","year":"2005","journal-title":"CR Chimie"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916393297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916393297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T21:20:47Z","timestamp":1557436847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354916393297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S0022354916393297"],"URL":"https:\/\/doi.org\/10.1002\/jps.21387","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}